(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/buy_a_domain.png

Buy and register domain names online from CRWE Domains. Web hosting, spam-free email, web marketing, secure SSL Certificates and more

www.crwedomains.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






Latest News Releases From The Newsroom

Bombardier to report Second Quarter 2016 Financial Results on August 5, 2016

July 28th, 2016

Montréal, Québec / CRWE PRESS RELEASE / July 28, 2016 - Bombardier (TSX: BBD.A)(TSX: BBD.B) will publish its financial results for the second quarter of 2016 on Friday, August 5, 2016, and will hold a live webcast/conference call to rev. Read more

Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016

July 27th, 2016

Sustained Response Through 31 Weeks for both Cognitive (MMSE) and Functional (ADCS-ADL) Measures NEW YORK, NY / CRWE PRESS RELEASE / July 27, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL. Read more

Epiq Systems Reaches Agreement to be Acquired for $16.50 Per Share by OMERS Private Equity and Harvest Partners

July 27th, 2016

Transaction valued at approximately $1.0 billion Upon completion of transaction, Epiq Systems and DTI to combine, creating a global legal services and technology leader Kansas City, Kan. / CRWE PRESS RELEASE / July 27, 2016 — Epiq Sys. Read more

Verizon to acquire Yahoo's operating business

July 25th, 2016

Transaction will create a new rival in mobile media technology reaching over 1B users* with an unrivaled roster of the world’s most beloved brands BASKING RIDGE, NJ, and SUNNYVALE, Calif. / CRWE PRESS RELEASE / July 25, 2016 &ndash. Read more

ONIVYDE(R) Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas who have Progressed Following Gemcitabine based Therapy

July 25th, 2016

The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy Zug, Swit. Read more

Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016

July 24th, 2016

Results Feature Favorable Safety, Maximum Tolerated Dose, Positive Dose Response as well as Positive Unexpected Therapeutic Response Events NEW YORK, NY / CRWE PRESS RELEASE / July 24, 2016 – Anavex Life Sciences Corp. (“Anavex” . Read more

SkyWest Airlines and ExpressJet Airlines Extend Heavy Maintenance Agreements Covering Bombardier CRJ Series Regional Jets

July 23rd, 2016

Montréal, Québec / CRWE PRESS RELEASE / July 22, 2016 - Bombardier Commercial Aircraft announced today that Bombardier Services Corporation has extended Heavy Maintenance Agreements with SkyWest, Inc. (NASDAQ: SKYW) carriers SkyWest Air. Read more

Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)

July 21st, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for t. Read more

Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

July 21st, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candida. Read more

CP reaches agreement with future CEO, Keith Creel; retains services of E. Hunter Harrison beyond retirement

July 21st, 2016

Calgary, AB / CRWE PRESS RELEASE / July 20, 2016 - Canadian Pacific Railway Limited (TSX: CP) (NYSE: CP) today announced that CP's Board of Directors has reached an agreement with CP's next chief executive officer, Keith Creel. Currently pres. Read more